2026 Annual Meeting | Industry Therapeutic Update from The Global CEO Initiative on Alzheimer's Disease: Alzheimer's Blood Tests in Clinical Practice: What Neurologists Need to Know

Date Wednesday 04/22/26

Time 11:45 AM - 12:45 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Suzanne E. Schindler, MD, PhD

Topic(s) General Neurology

Learning Objectives Blood-based biomarkers are increasingly entering clinical use, offering neurologists a new tool to support the evaluation and diagnosis of patients with cognitive concerns. This session will focus on the practical use of Alzheimer's blood tests, including when to order them, how to interpret results, and how to incorporate them into established diagnostic pathways. Faculty will discuss how blood tests can inform treatment decision-making, drawing on lessons from early clinical experience. The session will also address real-world considerations such as workflow integration, patient communication, and the integration with digital tools, equipping clinicians with actionable insights to apply these tools thoughtfully and effectively in practice.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	Industry Therapeutic Update from The Global CEO Initiative on Alzheimer's Disease: Alzheimer's Blood Tests in Clinical Practice: What Neurologists Need to Know

Faculty Disclosures
Suzanne E. Schindler, MD, PhD	Dr. Schindler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Schindler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Schindler has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. The institution of Dr. Schindler has received research support from National Institute on Aging. Dr. Schindler has received personal compensation in the range of $0-$499 for serving as a Member of the Biospecimen Review Committee with National Centralized Repository for Alzheimer Disease. Dr. Schindler has a non-compensated relationship as a Board Member with Greater Missouri Alzheimer's Association that is relevant to AAN interests or activities.
Jeffrey M. Burns, MD	Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Renew Research. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Norris, Keplinger, Hicks and Welder. The institution of Dr. Burns has received research support from National Institutes of Health. The institution of Dr. Burns has received research support from Biogen. The institution of Dr. Burns has received research support from Eli Lilly. The institution of Dr. Burns has received research support from Amylyx. The institution of Dr. Burns has received research support from Abbvie. The institution of Dr. Burns has received research support from Astra-Zeneca.

��ɫ��

��ɫ��